Optipharm.CO.LTD (153710) — Cash Flow-to-Debt Ratio
Optipharm.CO.LTD (153710) has a Cash Flow-to-Debt Ratio of 0.06x as of June 2026, meaning its operating cash flow of ₩905.29 Million could theoretically repay 0% of its total liabilities (₩15.42 Billion) in one year. See 153710 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Optipharm.CO.LTD Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Optipharm.CO.LTD across 11 annual periods. For the full cash flow conversion analysis, see 153710 cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Optipharm.CO.LTD (2015–2025)
Year-by-year debt coverage analysis for Optipharm.CO.LTD. Check how high is Optipharm.CO.LTD's earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.10x | ₩-1.55 Billion | ₩15.37 Billion | ▼ -171.5% |
| 2024 | -0.04x | ₩-595.50 Million | ₩15.98 Billion | ▲ +69.4% |
| 2023 | -0.12x | ₩-1.72 Billion | ₩14.13 Billion | ▲ +39.0% |
| 2022 | -0.20x | ₩-2.43 Billion | ₩12.17 Billion | ▼ -3.7% |
| 2021 | -0.19x | ₩-1.97 Billion | ₩10.21 Billion | ▲ +10.0% |
| 2020 | -0.21x | ₩-1.62 Billion | ₩7.54 Billion | ▼ -392.7% |
| 2019 | 0.07x | ₩447.47 Million | ₩6.11 Billion | ▼ -56.2% |
| 2018 | 0.17x | ₩1.20 Billion | ₩7.20 Billion | ▲ +352.4% |
| 2017 | 0.04x | ₩260.86 Million | ₩7.06 Billion | ▼ -69.6% |
| 2016 | 0.12x | ₩861.36 Million | ₩7.08 Billion | ▲ +312.5% |
| 2015 | -0.06x | ₩-751.51 Million | ₩13.12 Billion | — |